RBC Capital Upgrades Auxilium Pharmaceuticals (AUXL) to Outperform
Tweet
Share
E-mailGet Alerts AUXL Hot Sheet
Price: $36.47 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 77
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 77
Join SI Premium – FREE
RBC Capital upgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Sector Perform to Outperform, price target raised from $20 to $26.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $19.73 yesterday.
For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.
Shares of Auxilium Pharmaceuticals closed at $19.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades PulteGroup (PHM) to Outperform
- Easterly Government Properties (DEA) PT Raised to $24 at RBC Capital
- Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'
Create E-mail Alert Related Categories
UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
